Betting Generic: Part D, Patents and Proteins Drive Investment Surge

Generic drug companies have been spurned by Wall Street in the past in favor of their brand manufacturing counterparts. With high generic use rates in Medicare Part D and a perceived inevitability of follow-on biologics, investment in pharmaceutical copycats is on the upswing.

Ramsey Baghdadi

When it comes to investing in health care, generic drugs don’t exactly get Wall Street’s heart racing. But based on...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet